The common side effects

The UK label classes nausea, constipation, diarrhoea, vomiting, indigestion and abdominal pain as very common — meaning each affects more than one person in ten.

That list will look familiar to anyone who has read about semaglutide or tirzepatide. It is the signature of the GLP-1 class, and it follows directly from how these medicines work. GLP-1 slows the rate at which the stomach empties. That is part of what produces the feeling of fullness that makes the medicine effective — and it is also what produces the nausea. The two are not separable.

How often they happen, according to the UK label

The UK label groups side effects by how often they occurred, using the standard frequency bands. This is the authoritative UK list.

The UK label adds that digestive side effects were mostly mild or moderate, and that nausea, vomiting and diarrhoea were more frequent while the dose was being increased and became less frequent over time.

How common, in numbers — supplementary US figures

The UK label gives frequency bands rather than percentages. The table below comes from the United States prescribing information, which does give percentages by dose. It is included because the numbers are genuinely useful when weighing up treatment — but it is US data, and the UK bands above are the authoritative position.

Plain-English terms used above correspond to the following label terms: ¹ dyspepsia · ² abdominal distension · ³ eructation · ⁴ gastro-oesophageal reflux disease · ⁵ alopecia. The label reports only the three maintenance doses that were studied — 5.5, 9 and 17.2 mg. It does not report separate figures for the 0.8, 2.5 and 14.5 mg escalation steps.

Two things are worth reading out of that table rather than past it.

The placebo column is not zero. Around one person in ten on a dummy tablet reported nausea, and one in nine reported diarrhoea. Some of what people experience on any medicine would have happened anyway. The meaningful figure is the difference between the columns, not the size of the treatment column on its own.

The relationship with dose is not a straight line. Nausea and vomiting do rise with dose — vomiting nearly doubles, from 13% to 24%. But constipation actually peaks at the middle 9 mg dose at 27% and is lower at the maximum, and indigestion does the same, peaking at 16%. Abdominal pain and headache are essentially flat across the whole range.

This matters for how treatment is managed. It is not simply the case that a higher dose means worse side effects for everything, so someone struggling at 9 mg is not necessarily going to struggle more at 14.5 mg. Equally, a prescriber may hold someone at a dose that suits them rather than pushing to the maximum. These are individual judgements, and the table is the reason they have to be.

Taking all digestive side effects together, around 60–69% of trial participants reported at least one, against 37% on placebo. Severe digestive side effects were much rarer, at roughly 3% versus 1%.

How many people stop because of side effects

This is the honest measure of how tolerable a medicine is, because it reflects what people actually did rather than what they reported.

The UK label reports this for digestive side effects specifically, and by trial dose. In the weight-management studies, treatment was stopped because of digestive side effects by 3.7% of people on the lowest trial dose, 6.3% on the middle dose and 6.8% on the highest, against 0.6% on placebo. In the type 2 diabetes studies the equivalent figures were 2.1%, 4.1% and 6.2%, against 0.4%.

Two things are worth noting about those numbers. They are stated against the investigational capsule doses used in the trials, not the tablet strengths you would actually be prescribed — the label itself notes that the 24 mg and 36 mg capsules correspond to the 14.5 mg and 17.2 mg tablets. And they count only stopping because of digestive side effects, which is the main reason people stop but not the only one.

Put the other way round: on the highest trial dose, more than nine in ten people did not stop because of digestive side effects. That is a reasonable, rather than a remarkable, tolerability profile for this class.

One comparison is available and worth knowing. In ACHIEVE-3, the only head-to-head trial against oral semaglutide, orforglipron caused more digestive side effects, and roughly twice as many participants stopped because of them. It also produced greater reductions in HbA1c and greater weight loss. Better results, more side effects — that trade-off is the substance of the conversation with a prescriber, and anyone presenting orforglipron as simply gentler than the alternatives is not reading the data.

Why the dose is increased so slowly

Orforglipron starts at 0.8 mg and steps up through 2.5, 5.5, 9, 14.5 and 17.2 mg, with a minimum of one month at each level. Reaching the top dose therefore takes at least five months.

That schedule is not caution for its own sake. Digestive side effects are worst when the body first encounters the medicine and again after each increase, and they settle as it adapts. Giving a full month at each step lets that adaptation happen before the next increase. Rushing the escalation is the single most reliable way to make treatment intolerable.

It also means the highest dose is not automatically the goal. If someone is doing well at 5.5 mg and finds 9 mg difficult, staying at 5.5 mg is a legitimate clinical decision, not a failure.

Practical management

None of the following replaces advice from your own prescriber, who knows your history. But these are the measures generally used across the GLP-1 class.

Nausea

• Eat smaller amounts more often rather than large meals. A slowed stomach handles small volumes better.
• Stop eating when you feel full, not when the plate is empty. The signal arrives earlier on this medicine and ignoring it usually causes the nausea.
• Fatty, fried and very rich foods are the most common triggers.
• Plain, dry, starchy foods tend to be tolerated best in the difficult weeks.
• Sip fluids steadily through the day rather than drinking large amounts at once.

Constipation

• Fluid intake matters more than usual, and is easy to let slip when appetite drops.
• Increase fibre gradually. A sudden large increase can worsen bloating.
• Movement helps, and gentle daily activity is more effective than occasional exercise.
• If it persists, ask a pharmacist before buying a laxative — which type suits depends on the pattern.

Diarrhoea and vomiting

• Keep fluids up. Dehydration is the complication that matters here, and it can affect the kidneys.
• Persistent vomiting, or being unable to keep fluids down, needs medical advice rather than waiting it out.

When to seek help rather than manage it yourself

Contact a healthcare professional promptly if you experience:

• Severe, persistent abdominal pain, particularly if it spreads to your back or comes with vomiting — this needs assessment for pancreatitis.
• Pain in the upper right abdomen, fever, yellowing of the skin or eyes, or pale stools — possible gallbladder problems.
• Vomiting or diarrhoea that stops you keeping fluids down.
• Signs of an allergic reaction: swelling of the face, lips, tongue or throat, difficulty breathing, or a widespread rash. Seek emergency help.
• Symptoms of low blood sugar — shakiness, sweating, confusion, palpitations — particularly if you also take insulin or a sulfonylurea.
• A noticeable change in your eyesight, if you have diabetic retinopathy.

Less common but important risks

Thyroid tumours — the UK label does not carry this warning. The United States prescribing information has a boxed warning about thyroid C-cell tumours seen in rodent studies, and contraindicates the medicine in anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. The UK Summary of Product Characteristics contains no such warning and no such contraindication — thyroid tumours are not mentioned in it at all, and the only UK contraindication is an allergy to the medicine or its ingredients. We flagged this as unresolved before the UK document existed. It is now resolved, and the answer is that this is a US-only position.

Pancreatitis. Listed as an uncommon side effect — between 1 in 1,000 and 1 in 100. The UK label notes that necrotising pancreatitis and pancreatitis with a fatal outcome have been reported with GLP-1 medicines as a class, that orforglipron should be stopped if pancreatitis is suspected and not restarted if it is confirmed, and that raised pancreatic enzymes on a blood test on their own do not predict pancreatitis. This is why the abdominal pain guidance above matters.

Gallbladder disease. Gallstones are a common side effect — between 1 in 100 and 1 in 10. The label links gallbladder events to weight reduction itself, and advises investigation if inflammation of the gallbladder is suspected.

Kidney injury from dehydration. Vomiting and diarrhoea can cause dehydration, and dehydration can worsen kidney function, including causing acute kidney injury. This is a knock-on effect rather than a direct action on the kidneys, which is why keeping fluids up is not a throwaway instruction. No dose change is needed for any level of kidney function, including dialysis.

Low blood pressure. Orforglipron can lower blood pressure, and this was reported more often in people already taking medicines for high blood pressure. Dizziness is a common side effect.

Severe heart failure. There is no experience in NYHA class IV heart failure, and the medicine is not recommended in that group.

Low blood sugar. In the type 2 diabetes trials, hypoglycaemia was reported by about 2% of people taking orforglipron against 0.2% on placebo, rising to 7% among those also taking a sulfonylurea, against 0.5% among those who were not. Doses of insulin or sulfonylureas often need reducing.

Anaesthesia and sedation. Because orforglipron delays stomach emptying, there is a risk of stomach contents entering the lungs during a general anaesthetic or deep sedation. Tell any surgical, dental or endoscopy team that you take it, well before the procedure.

Diabetic retinopathy. Rapid improvement in blood glucose control can temporarily worsen existing diabetic eye disease. Anyone with retinopathy should have it monitored.

The interactions that make orforglipron different

This is where orforglipron genuinely departs from the injectable GLP-1s, and it is the part most often left out of articles about it.

Semaglutide and tirzepatide are peptides. They are broken down like proteins and have few drug interactions. Orforglipron is a small molecule, and the UK label describes it as a substrate of the liver enzymes CYP3A4 and CYP2J2 and of the transporters P-gp, OATP1B1 and OATP1B3 — which puts it in the same interaction territory as a great many ordinary medicines.

• Strong CYP3A4 inhibitors — ketoconazole, clarithromycin, itraconazole. In a study, clarithromycin raised orforglipron exposure about 3.5-fold. The orforglipron dose is capped at 9 mg while one of these is being taken.
• Strong CYP3A4 inducers — carbamazepine, for instance. These lower orforglipron levels, and concomitant use should be avoided.
• OATP1B inhibitors. A separate group with the same consequence: the dose is capped at 9 mg. This one is easily missed, because it has nothing to do with CYP3A4.
• Simvastatin. The UK label says the simvastatin dose should be halved when taken with orforglipron. (The United States label frames this as a maximum simvastatin dose instead — another place the two differ.)
• Oral contraceptives. Because orforglipron slows stomach emptying, oral contraceptive pills may not be absorbed reliably. Women using oral contraception are advised to switch to a non-oral method, or add a barrier method, for 30 days after starting and for 30 days after every dose increase. With six dose levels, that applies repeatedly through the first five months, not just at the start. This is easily the most commonly overlooked instruction attached to this medicine.
• Insulin and sulfonylureas. Doses may need reducing.

This is not a complete list. Anyone considering treatment should give a prescriber a full list of everything they take — prescribed, bought over the counter, and any supplements.